X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs SUN PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES SUN PHARMA DIVIS LABORATORIES/
SUN PHARMA
 
P/E (TTM) x 30.0 25.6 117.1% View Chart
P/BV x 5.2 3.7 138.9% View Chart
Dividend Yield % 1.0 0.6 155.2%  

Financials

 DIVIS LABORATORIES   SUN PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
SUN PHARMA
Mar-17
DIVIS LABORATORIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,222842 145.1%   
Low Rs784572 137.0%   
Sales per share (Unadj.) Rs153.1131.6 116.3%  
Earnings per share (Unadj.) Rs39.932.7 122.1%  
Cash flow per share (Unadj.) Rs44.638.0 117.4%  
Dividends per share (Unadj.) Rs10.003.50 285.7%  
Dividend yield (eoy) %1.00.5 201.5%  
Book value per share (Unadj.) Rs201.8152.7 132.1%  
Shares outstanding (eoy) m265.472,399.26 11.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.65.4 121.9%   
Avg P/E ratio x25.121.6 116.1%  
P/CF ratio (eoy) x22.518.6 120.8%  
Price / Book Value ratio x5.04.6 107.3%  
Dividend payout %25.010.7 233.9%   
Avg Mkt Cap Rs m266,2661,696,877 15.7%   
No. of employees `0009.717.5 55.6%   
Total wages/salary Rs m4,68749,023 9.6%   
Avg. sales/employee Rs Th4,175.018,028.3 23.2%   
Avg. wages/employee Rs Th481.52,798.8 17.2%   
Avg. net profit/employee Rs Th1,089.34,479.5 24.3%   
INCOME DATA
Net Sales Rs m40,643315,784 12.9%  
Other income Rs m7496,232 12.0%   
Total revenues Rs m41,392322,016 12.9%   
Gross profit Rs m14,460100,893 14.3%  
Depreciation Rs m1,23312,648 9.8%   
Interest Rs m233,998 0.6%   
Profit before tax Rs m13,95390,479 15.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,34912,116 27.6%   
Profit after tax Rs m10,60478,462 13.5%  
Gross profit margin %35.631.9 111.4%  
Effective tax rate %24.013.4 179.2%   
Net profit margin %26.124.8 105.0%  
BALANCE SHEET DATA
Current assets Rs m40,105329,537 12.2%   
Current liabilities Rs m6,595178,870 3.7%   
Net working cap to sales %82.547.7 172.8%  
Current ratio x6.11.8 330.1%  
Inventory Days Days11979 150.1%  
Debtors Days Days8183 96.9%  
Net fixed assets Rs m19,995204,766 9.8%   
Share capital Rs m5312,399 22.1%   
"Free" reserves Rs m53,043363,997 14.6%   
Net worth Rs m53,574366,397 14.6%   
Long term debt Rs m014,361 0.0%   
Total assets Rs m61,585614,102 10.0%  
Interest coverage x618.423.6 2,616.9%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.70.5 128.3%   
Return on assets %17.313.4 128.5%  
Return on equity %19.821.4 92.4%  
Return on capital %26.124.8 105.0%  
Exports to sales %00-   
Imports to sales %25.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259NA-   
Fx inflow Rs m35,38444,118 80.2%   
Fx outflow Rs m10,39924,484 42.5%   
Net fx Rs m24,98519,634 127.3%   
CASH FLOW
From Operations Rs m11,49370,822 16.2%  
From Investments Rs m-11,372-42,216 26.9%  
From Financial Activity Rs m-93-22,854 0.4%  
Net Cashflow Rs m286,107 0.5%  

Share Holding

Indian Promoters % 52.0 63.7 81.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 5.1 230.0%  
FIIs % 19.0 23.0 82.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 8.3 207.2%  
Shareholders   31,796 133,026 23.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON LTD  PFIZER  ALKEM LABORATORIES  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 23, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS